Skip to content

The Effect of Multi-factor Intervention on Peripheral Neuropathy-Brain Injury in type 2 Diabetes :Prospective, Cohort Study

The Effect of Multi-factor Intervention on Peripheral Neuropathy-Brain Injury in type 2 Diabetes :Prospective, Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087595
Enrollment
Unknown
Registered
2024-07-31
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Interventions

Newly diagnosed Type 2 Diabetes and DSPN merger:None
Painful type 2 diabetic peripheral neuropathy:None
Non painful diabetic peripheral neuropathy:None

Sponsors

Minhang Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? neuropathy at or after the diagnosis of diabetes; (2) age between 18 and 70 years old; (3) right-handed; ? The clinical symptoms and signs were consistent with the manifestations of DSPN; There were symptoms or signs of DSPN along with abnormalities in nerve conduction studies or small-fiber nerve function tests. (5) without the claustrophobic, willing to in the group, MRI after 3 months and 6 months. (6). Willing to not drink alcohol within half a year. ? Junior high school or above, with reading and writing ability. Willing to stop using neuropathic pain medication before MRI scans.

Exclusion criteria

Exclusion criteria: ? History of recurrent severe hypoglycemia, hypoglycemia unconsciousness; ?History of cervical and lumbar vertebrae (nerve root compression, spinal stenosis, cervical and lumbar degeneration); ? cerebral infarction; ? Guillain-Barre syndrome;?Severe arteriovenous vascular lesions (venous embolism, lymphangitis);?Vitamin B12 deficiency; ? Viral infection (such as human immunodeficiency virus, etc.); ? Neurotoxic effect caused by chemotherapy drugs and renal insufficiency caused by metabolic poisons to nerve injury history.

Design outcomes

Secondary

MeasureTime frame
BMI;Waist-hip ratio;Hypoglycemia;

Primary

MeasureTime frame
Sural nerve conduction velocity and amplitude;Norfolk QOL-DN;Metabolites of brain magnetic resonance spectroscopy;

Countries

China

Contacts

Public ContactLi xuesong

Minhang Hospital, Fudan University

li_xuesong@fudan.edu.cn+86 131 6647 5191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026